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THE INFLUENCE OF T CELL RECEPTOR SIGNALING ON HUMAN 
IMMUNODEFICIENCY VIRUS INFECTION 
MELISSA B. HERRING 	  
ABSTRACT 	  
	  
 A significant barrier to curing Acquired Immunodeficiency Syndrome 
(AIDS) is the presence of latent reservoirs of cells infected with an integrated but 
transcriptionally silent provirus that is unaffected by the immune response or by 
antiretroviral drugs. Therefore, while antiretroviral therapy is able to suppress 
patient viral loads to clinically undetectable levels, upon cessation of treatment, 
viral loads rebound rapidly as virus is released from the latent reservoir. An 
understanding of the Human Immunodeficiency Virus (HIV) transcriptional 
regulatory events that contribute to viral latency is an important step towards 
eradicating the latent reservoir. Of particular interest are the mechanisms early in 
HIV infection that direct the cell towards productive or latent infection.  
The current study aims to determine whether the strength of T cell 
receptor (TCR) signaling at the time of HIV infection is correlated with the level of 
HIV transcription and to characterize the T cell receptor signaling pathways that 
regulate HIV transcription. We hypothesize that the strength of signaling at the 
time of infection determines the magnitude of early HIV transcription.  
	  	   v 
Simultaneous infection and stimulation of Jurkat E6.1 T cells expressing 
the C6.5 chimeric antigen receptor shows a 1.5-fold increase in transcription 
compared to unstimulated controls while Jurkat E6.1 T cells expressing the B1D2 
chimeric antigen receptor shows a nearly 3-fold increase in transcription 
compared to unstimulated controls. These results suggest that the strength of 
signaling through the TCR at the time of infection determines the magnitude of 
HIV transcription early in infection and may contribute to the establishment of 
productive or latent infection within the cell.  
Simultaneous infection and stimulation of Jurkat E6.1 T cells expressing 
the C6.5 or B1D2 chimeric antigen receptors in the presence of select inhibitors 
of T cell receptor signaling molecules indicate that TCR signaling through PI3 
kinase and protein kinase C pathways may negatively and positively regulate HIV 
transcription, respectively. Understanding the specific TCR signaling pathways 
that lead to the initial establishment of latency within newly infected cells may 
lead to the discovery of novel therapeutic targets aimed at eliminating the latent 
reservoir. 
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INTRODUCTION 
 The AIDS epidemic began in late 1981 with reports of several 
previously healthy homosexual men in both California and New York suffering 
from Kaposi’s sarcoma, Pneumocystis pneumonia, and other opportunistic 
infections only seen in severely immunocompromised individuals (Friedman-
Kien, 1981; Gottlieb et al., 1981). Within months, this severe form of acquired 
immunodeficiency became known as Acquired Immunodeficiency Syndrome 
(AIDS). However, it was two years before the retrovirus responsible for the 
disease, Human Immunodeficiency Virus (HIV), was discovered (Barré-
Sinoussi et al., 1983) and another four years before the first antiretroviral 
therapy (ART) became available (Ezzell, 1987). While it took six years to 
develop a drug to treat the virus responsible for AIDS, it only took two years 
for the virus to begin developing resistance to the drug (Bach, 1989). By the 
time highly active anti-retroviral therapy (HAART) was introduced as the 
standard for treating the virus and preventing drug resistance, more than 4.5 
million people had been diagnosed with the disease worldwide (Centers for 
Disease Control and Prevention (CDC), 1995). 
 Although it has been thirty-five years since the beginning of the AIDS 
epidemic, finding a cure for the disease remains elusive. While advancements 
in antiretroviral therapy along with increased prevention efforts have led to a 
steady decline in both the number of AIDS related deaths and the number of 
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individuals newly infected with HIV per year, HIV is still responsible for an 
estimated 1.2 million deaths per year with 2 million individuals becoming 
newly infected with the virus each year (“WHO | HIV/AIDS,” 2015). The region 
most affected by the AIDS epidemic is sub-Saharan Africa, which accounts 
for 70% of cases worldwide. However, even in developed countries where 
HIV has become more of a chronic, treatable condition thanks to the success 
of antiretrovirals, we are just beginning to see the adverse effects of long-term 
antiretroviral treatment, such as the increased risk of cardiovascular disease, 
liver disease, and cancer (Cahill & Valadéz, 2013). It is, therefore, just as 
important as ever that a cure be found for this disease that affects an 
estimated 36.9 million people worldwide. 
HIV Structure and Life Cycle 
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus composed of 
two copies of positively stranded RNA encased in a cone-shaped core The 
viral core consists of the capsid and its contents and is characterized by its 
fullerene cone geometry of approximately 250 hexagomers and exactly 
twelve pentamers. The virus is surrounded by a lipid envelope that is derived 
from the phospholipid bilayer of the infected host cell and that has 
approximately ten trimeric envelope proteins (Env) with subunits gp120 and 
gp41 (Briggs & Kräusslich, 2011). Figure 1 shows the structure and 
components of the virus. 
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 The HIV-1 genome consists of two long terminal repeat (LTR) 
regulatory regions located on either side of a coding region. Within the coding 
region are the gag-pol and env genes along with the genes for several 
accessory proteins. Gag-pol encodes both the Gag polyprotein precursor, 
which is proteolytically processed into the structural proteins MA, CA, NC, 
and p6 and the spacer peptides SP1 and SP2, and the Gag-pol polyprotein 
precursor, which additionally includes the protease (PR), reverse 
transcriptase (RT), and integrase (IN) enzymes. Env encodes the gp160 
precursor to the gp120 and gp41 envelope protein subunits (Sierra, Kupfer, & 
Kaiser, 2005). 
 The tat, rev, nef, vpu, vif, and vpr genes each encode a corresponding 
accessory protein. Tat is a transcriptional activator which binds to the trans-
activation response (TAR) element within the LTR and controls further HIV-1 
gene transcription. Rev is an accessory protein which binds to the Rev 
response element (RRE) found within singly spliced and unspliced viral 
mRNA transcripts, facilitating their transport through the nuclear membrane 
and allowing for their translation in the cytosol. Nef, as one of its many 
putative functions, aids in both the endocytosis and degradation of CD4 co-
receptors and MHCI and MHCII molecules found on the cell surface, a 
function essential for viral assembly and budding. Vpu, along with inducing 
the degradation of newly synthesized CD4 receptors within the endoplasmic 
reticulum, counteracts the host restriction factor tetherin, which blocks viral 
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particle release by tethering them to the plasma membrane. Vif counteracts 
the host restriction factor APOBEC3G, which blocks viral replication through 
cytidine deamination which leads to guanine to adenosine hypermutations 
during reverse transcription that render the viral genome highly unstable and 
unable to integrate into the host genome. Vpr directs the preintegration 
complex to the nuclear membrane, enabling it to enter the nucleus and 
integrate into the host genome (Laguette & Benkirane, 2012; Sierra et al., 
2005). 
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Figure 1: Structure of Human Immunodeficiency Virus. The virus is 
composed of two copies of RNA within a cone-shaped core and surrounded 
by a lipid envelope derived from the host cell membrane. Figure taken from 
the National Institute of Allergy and Infectious Disease. 
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 The virus assembles and buds from an infected cell as an immature, 
non-infectious particle. During assembly, the viral protease is activated, 
leading to the proteolytic cleavage of the Gag polyprotein to release the 
structural proteins MA, CA, NC, and p6 and the spacer peptides SP1 and 
SP2. As the virus buds from the plasma membrane of the infected cell, it 
acquires a lipid envelope derived from the host cell membrane. Upon 
budding, the structural proteins then reassemble to form the matrix layer of 
the inner viral membrane, the capsid layer encasing the nucleocapsid and the 
enzymes reverse transcriptase and integrase, and the nucleocapsid layer 
coating the viral RNA genome. This rearrangement results in the formation of 
a mature, infectious virion capable of infecting a new cell (Ganser-Pornillos, 
Yeager, & Sundquist, 2008). A new cell becomes infected when viral Env 
binds to cell surface CD4 and either the CXCR4 or CCR5 chemokine 
receptor, which function as co-receptors for HIV. Upon binding of CD4 and 
CXCR4 or CCR5, the viral envelope fuses with the cell membrane. Following 
fusion, the viral core is released into the cytosol and the capsid is uncoated, 
enabling the viral genome to enter the cytosol. Within the cytosol, the viral 
genome undergoes reverse transcription of its single-stranded RNA into 
double-stranded DNA, forming a provirus that is incorporated into the host’s 
genome by an integrase. Upon activation of the cell, the viral genome is 
transcribed and translated, leading to protein synthesis and assembly of the 
viral particles. Once the virus is enveloped by the host cell membrane, it is 
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released and capable of another round of infection (Ganser-Pornillos et al., 
2008; Gomez & Hope, 2005). The overall life cycle for HIV replication is 
highlighted in Figure 2. 
 
Figure 2: Life Cycle of Human Immunodeficiency Virus The HIV life cycle 
is comprised of the following steps: fusion with the host membrane, entry into 
the host cell, reverse transcription, integration, transcription and translation, 
formation of immature virion, and budding of mature virion from the host cell 
surface membrane. Figure taken from the National Institute of Allergy and 
Infectious Diseases. 
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 There are currently six major classes of antiretroviral drugs, each 
targeting a specific stage of the viral life cycle. Both the CCR5 antagonists 
and the fusion inhibitors target viral entry; the CCR5 antagonists by 
interacting with the host CCR5 co-receptor, preventing recognition and 
binding of the viral gp120, and the fusion inhibitors by binding to the HR1 
sequence of the viral gp41, inhibiting fusion of the viral and host cell 
membranes. The two classes of reverse transcriptase inhibitors, the 
nucleoside reverse transcriptase inhibitors (NRTIs) and the non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) work by blocking the reverse 
transcription of viral RNA into DNA. As nucleoside analogues that lack a 3’-
hydroxyl group, NRTIs work by competitively inhibiting reverse transcriptase 
and, once incorporated into the growing DNA strand, blocking the addition of 
subsequent nucleotides. NNRTIs, on the other hand, work by binding to a 
hydrophobic pocket near the active site of reverse transcriptase and 
noncompetitively inhibiting the enzyme’s activity. The integrase inhibitors or 
“strand transfer inhibitors” competitively inhibit integrase activity and prevent 
the integration of the proviral DNA into the host genome. The protease 
inhibitors are substrate analogues that bind to the active site of the enzyme, 
preventing the proteolytic processing of the Gag proteins and, therefore, the 
assembly of the mature virion (Sierra-Aragón & Walter, 2012). Standard 
antiretroviral treatment regimes, which incorporate multiple drugs with 
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different targets, have proven effective in both suppressing viremia and 
decreasing the risk of developing drug resistance. 
Viral Latency 
Although HAART and its predecessor ART have done wonders in 
suppressing patient viremia and in delaying the progression of HIV infection 
to AIDS, both have been unsuccessful at completely eliminating the virus 
from infected individuals. While antiretrovirals are capable of preventing 
ongoing viral replication, they are unable to prevent replication within already 
infected cells. Therefore, even when patient viremia is suppressed to 
undetectable levels (<50 copies/mL), residual viremia (~1 copy/mL) remains 
present in the blood, as is evident by the rapid rebound of patient viral loads 
seen upon cessation of antiretroviral therapy (Siliciano, 2010; Van Lint, 
Bouchat, & Marcello, 2013). Figure 3 details the changes in patient viremia 
over the course of antiretroviral therapy and the rapid rebound in viremia 
upon its cessation. 
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Figure 3: Plasma Viremia in HIV+ Individuals Treated with Antiretroviral 
Therapy. Upon initiation of antiretroviral therapy, patients show an initial rapid 
decline in plasma viremia followed by a second phase, in which the rate of 
decline slows, and a third phase, in which viremia is suppressed to clinically 
undetectable levels. Upon cessation of antiretroviral therapy, patient viremia 
rebounds rapidly. Figure amended from (Van Lint et al., 2013). 
 
 This viral rebound is due in part to the establishment of viral reservoirs 
within latently infected cells. The most significant contributors to the latent 
reservoir are the resting CD4+ T cells. Although resting CD4+ T cells are 
resistant to infection by HIV-1, activated CD4+ T cells are highly susceptible 
to infection. Although most die quickly from either cytotoxic effects of the virus 
or from the immune response, a small population returns to a resting state 
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and survives as memory T cells, resulting in virus that is integrated into the 
host genome but is transcriptionally silent. This transcriptionally silent virus 
can persist within the host for years or even decades, hidden from both the 
immune system and from antiretroviral drugs. However, once a memory cell 
becomes reactivated through antigen exposure, the cell is capable of 
producing virus. If the patient is on antiretroviral therapy, the virus will be 
unable to infect new cells, but, if treatment has been suspended, the virus 
released from this latent reservoir will be capable of infecting new cells, 
leading to a rebound in plasma viremia. (Siliciano & Greene, 2011) Although 
the exact mechanism for the establishment and maintenance of latency in 
CD4+ T cells is unclear, it is thought to involve a combination of chromatin 
remodeling, transcriptional interference, and the regulation of transcription 
initiation and elongation.  
Chromatin Remodeling 
Although it was initially suggested that HIV-1 integrates into condensed 
heterochromatic regions of the host genome, it has since been shown that the 
provirus tends to integrate into euchromatic regions of actively transcribed 
genes (Han et al., 2004). Nevertheless, even when integrated into regions of 
euchromatin, the integrated provirus is associated with positioned 
nucleosomes that form within the 5’ LTR (Verdin, Paras, & Van Lint, 1993). 
These nucleosomes, nuc-0 and nuc-1, are regulated by SWI/SNF remodeling 
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complexes and posttranslational modifications of the histone tails, particularly 
histone tail acetylation (Siliciano & Greene, 2011). Histone tail acetylation by 
histone acetyltransferases (HATs), along with SWI/SNF remodeling complex 
recruitment, leads to the displacement of nuc-1 and to the activation of HIV-1 
transcription. Repression of transcription is associated with the recruitment of 
SWI/SNF remodeling complexes and histone tail deacetylation by histone 
deacetylases (HDACs), resulting in a more condensed chromatin structure 
that interferes with efficient gene transcription. Thus, posttranslational 
modifications of nucleosomes are hypothesized to contribute to the 
maintenance of HIV latency (Schiralli Lester & Henderson, 2012). 
Transcriptional Interference 
The findings that the HIV-1 provirus preferentially integrates into 
actively transcribed host genes suggest that transcriptional interference may 
play a role in the maintenance of viral latency. Transcriptional interference 
occurs when ongoing host genome transcription prevents formation of the 
pre-initiation complex at the HIV 5’ LTR, thereby interfering with viral 
transcription. Two different forms of transcriptional interference can occur, 
depending upon the direction of proviral integration with regard to the host 
transcriptional regulatory elements. If the viral genome integrates in the same 
orientation as the host gene, this can result in transcription of upstream host 
genes by RNA polymerase II through the HIV 5’ LTR, leading to the 
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displacement of key transcription factors on the HIV LTR, the prevention of 
pre-initiation complex assembly on the viral promoter, and consequently, the 
inhibition of effective proviral transcription (Lenasi, Contreras, & Peterlin, 
2008; Siliciano & Greene, 2011). On the other hand, if proviral integration is in 
the opposing direction to that of host gene transcription, collisions between 
the two RNA Pol II complexes can occur, resulting in premature transcription 
termination (Han et al., 2008; Siliciano & Greene, 2011; Schiralli Lester & 
Henderson, 2012). Thus, regardless of the orientation of the integrated 
provirus within the host gene, transcriptional interference seems to be a 
significant mechanism of viral persistence. 
Transcription Initiation 
Another possible mechanism for establishing and maintaining latency 
is through the regulation of transcription initiation. This regulation is 
accomplished through the HIV 5’ LTR, which is divided into the Tat activating 
region (TAR), the promoter, the enhancer, and the modulatory element. 
Inducible host transcription factors bind to sites within these regions of 5’ LTR 
to regulate the initiation of HIV-1 transcription (Figure 4). The transcription 
factor SP1, for example, binds to three sites within the core promoter to 
activate transcription, whereas the factors AP-1, NFAT, and NF-κB bind to 
sites within the enhancer to regulate transcription initiation (Siliciano & 
Greene, 2011; Schiralli Lester & Henderson, 2012).  
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Figure 4: Organization of the HIV 5’ LTR. The 5’ LTR is divided into the 
TAR, promoter, enhancer, and modulatory element. Transcription factors bind 
to sites within the LTR to regulate initiation of HIV transcription. Figure 
amended from (Schiralli Lester & Henderson, 2012) 
 
The NF-κB/Rel family of transcription factors is a perfect example of a 
transcription factor that has both activating and inhibitory effects on the HIV 5’ 
LTR. NF-κB is composed of two subunits, RelA (p65) and p50. In resting 
cells, the RelA subunit is sequestered in the cytosol by the inhibitory complex, 
IκB. Not only does this limit the amount of active NF-κB available in the 
nucleus to bind to the 5’ LTR and activate transcription initiation, thereby 
repressing transcription, but it also enables homodimers of the p50 subunit to 
bind to the NF-κB sites within the LTR. These p50/p50 homodimers recruit 
HDACs, which promote histone tail deacetylation and chromatin 
condensation, leading to further transcriptional repression. However, once the 
cell is activated, RelA is released from IκB, enabling it to from heterodimers 
with p50, which translocate to the nucleus and displace the p50/p50 
homodimers(R. F. Siliciano & Greene, 2011; Schiralli Lester & Henderson, 
2012). Bound p50/RelA heterodimers recruit p300/CBP, leading to histone tail 
acetylation and increased binding of RNA Pol II and TFIIH/CDK7. Binding of 
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TFIIH/CDK7 leads to increased promoter clearance and phosphorylation of 
serine 5 residues on the carboxy-terminal domain (CTD) of RNA Pol II, 
resulting in transcriptional activation (Kim et al., 2006; R. F. Siliciano & 
Greene, 2011).  
Transcription Elongation 
Transcription elongation presents another possible regulatory step in 
the establishment and maintenance of latency (Figure 5). Once transcription 
has been initiated, the negative elongation factors NELF and DSIF bind to the 
HIV 5’ LTR and cause RNA Pol II pausing, resulting in limited proviral 
transcription but nevertheless allowing for the production of Tat. Once 
sufficient amounts of Tat have been produced, it binds to the TAR element to 
form the Tat-TAR complex, which in turn recruits P-TEFb, a kinase 
sequestered in an inactive ribonucleoprotein complex composed of 7SK RNA 
and HEXIM1 (7SK snRNP complex). Tat interacts with both the cyclin T1 and 
CDK9 subunits of P-TEFb, causing its release from the 7SK snRNP complex. 
P-TEFb subsequently phosphorylates both DSIF and NELF, converting DSIF 
to a positive elongation factor that prevents premature release of RNA Pol II 
at termination sequences and causing dissociation of NELF, and coupled with 
the phosphorylation of serine 2 residues on the CTD of RNA Pol II allows for 
efficient transcription elongation (Siliciano & Greene, 2011; Schiralli Lester & 
Henderson, 2012). The high levels of both Tat and P-TEFb activity seen in 
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activated cells compared to the low levels seen in resting cells likely indicate 
that Tat and P-TEFb may be key regulators of viral latency. 
 
Figure 5: Regulation of HIV Transcription Elongation. Top: Following 
transcription initiation, NELF and DSIF bind to the 5’ LTR, resulting in RNA 
Pol II pausing just downstream of the transcriptional start site. Bottom: Tat 
binds to the TAR element and recruits P-TEFb, which phosphorylates serine 
2 residues on the CTD of RNA Pol II, NELF, and DSIF, enabling transcription 
elongation to proceed. Figure amended from (Schiralli Lester & Henderson, 
2012). 
 
An increased understanding of the mechanisms involved in viral 
latency has led to the search for compounds capable of reactivating latently 
infected cells in the hope that this would lead to their destruction by the 
immune system or by the cytotoxic effects of the virus. Early trials using 
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HDAC inhibitors to reactivate latent cells showed promising results (Lehrman 
et al., 2005) but subsequent studies failed to show significant reductions in 
the size of the latent reservoir (Siliciano et al., 2007; Sagot-Lerolle et al., 
2008; Archin et al., 2010). 
 The failure of HDAC inhibitors to significantly reduce the latent 
reservoir suggests that the role of transcriptional regulation in latency is more 
complex than previously thought and highlights the need for additional 
research. As most latency research has focused on the transcriptional 
regulatory events that act to maintain latency, there is a particular need for 
research into the initial establishment of latency early in infection. Recent 
evidence indicates that the activation state of the cell at the time of infection 
may influence whether or not latency is established within the cell. 
T Cell Receptor Signaling and Its Influence on Latency 
Activation of CD4+ T cells by engagement of the T cell receptor (TCR) 
and CD4 co-receptor and the CD28 co-stimulatory molecule results in a 
signaling cascade of events, beginning with the activation of Lck, a Src kinase 
attached to the cytosolic tails of the CD4 co-receptor. Lck phosphorylates 
both the tyrosine kinase ZAP-70 and the tyrosine residues of the 
immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD4-
associated CD3ζ chains. Activated ZAP-70 binds to the phosphorylated 
ITAMs and phosphorylates a host of adaptor proteins, most important of 
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which are LAT and SLP-76 (Huang & Wange, 2004; Brownlie & Zamoyska, 
2013). These adaptor proteins activate PLCγ1, an enzyme that catalyzes the 
hydrolysis of PIP2 into the second messangers IP3 and DAG. The hydrolysis 
of PIP2 presents a branch point in the signaling cascade, as IP3 and DAG 
each activate one or more separate pathways.  
The formation of IP3 results in the release of calcium from the 
endoplasmic reticulum into the cytosol. The rise in cytosolic calcium leads it to 
bind to calmodulin, and the calcium-calmodulin complex activates the 
phosphatase calcineurin. Activated calcineurin dephosphorylates the 
transcription factor NFAT, enabling its translocation to the nucleus. DAG 
formation leads to the activation of both protein kinase Cθ (PKCθ) and Ras. 
Activated PKCθ activates IκB kinase (IKK), which phosphorylates the NF-κB 
inhibitory protein IκB, targeting it for degradation. The degradation of IκB 
leads to NF-κB release and translocation to the nucleus. Another kinase 
involved in NF- κB activation is PI3 kinase (PI3K). PI3K phosphorylates PIP2 
to form PIP3. The serine-threonine kinase Akt binds to PIP3 and becomes 
activated. Akt interacts with PKCθ to enhance activation of NF- κB. DAG 
activation of Ras involves the exchange of bound GDP for GTP and leads to 
activation of the MAP kinase pathway, at the end of which are the kinases 
ERK and JNK. Activation of ERK leads to the upregulation of c-Fos 
expression while activation of JNK leads to the phosphorylation of c-Jun. 
Together c-Fos and phosphorylated c-Jun form the transcription factor AP-1 
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(Huang & Wange, 2004). Through these separate pathways, TCR signaling 
ultimately leads to the upregulation of the transcription factors NFAT, NFkB, 
and AP-1, resulting in the regulation of gene expression (Figure 6). These 
pathways also converge to regulate HIV transcription by binding to elements 
within the HIV 5’ LTR. 
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Figure 6: T Cell Receptor Signaling Cascade. Engagement of the TCR 
results in a signaling cascade of events that ultimately leads to the 
upregulation of the transcription factors NFAT, NF-κB, and AP-1. Figure taken 
from (Huang & Wange, 2004). 
 
protein that is constitutively targeted to the lipid rafts by virtue of
palmitoylation of two juxtamembrane cysteine residues (8, 13, 14).
It has no protein interaction domains other than the multiple
tyrosine residues that are phosphorylated by ZAP-70 following
TCR signaling. When phosphorylated, these tyrosines serve as
binding sites for specific SH2 domain-containing proteins. There
are a total of 8 tyrosine residues in LAT that re conserved
between humans, mice, rats, and bovines (14). The C-terminal 5
tyrosine residues play critical roles in the ability of LAT to bind
to PLC!1 and the linker proteins Gads and Grb2. SLP-76 asso-
ciates with LAT via Gads. SLP-76 can also directly bind to
PLC!1, indicating the existence of higher order interactions be-
tween these and possibly other signaling proteins in the signa-
losome. In addition to the proteins already mentioned, phospho-
rylated LAT also binds to PI3K, Grap, 3BP2, Shb, SOS, c-Cbl,
Vav, and Itk, localizing these molecules in close proximity and a
defined orientation to one another within the lipid raft domain of
the plasma membrane. Jurkat T cells deficient for LAT expres-
sion exhibit severe signaling defects to Ca2! mobilization, mito-
gen-activated protein kinase activation, and NFAT activation (8,
13, 14).
Unlike LAT, SLP-76 is a cytosolic protein (12). The structure of
SLP-76 includes an acidic N-terminal region, which includes three
sites of tyrosine phosphorylation (Tyr-113, Tyr-128, and Tyr-145).
When phosphorylated, these sites can bind the SH2 domains of
Vav-1, Nck, and Itk. The acidic region is followed by an extended
proline-rich region, which binds the SH3 domains of Gads, Itk, and
PLC!1. The C-terminal portion of SLP-76 is comprised of a single
SH2 domain, which binds primarily to ADAP, which has been
reported to play a key role in inside-out signaling to integrins (17).
Jurkat T cells that lack SLP-76 are defective in their ability to
activate: 1) PLC!1 and consequently Ca2! mobilization and NFAT
activation; 2) the Ras/Raf/Mek/Erk pathway; 3) NF"B; and 4) in-
side-out signaling to integrins (12, 17, 18).
Cytoskeletal Reorganization and Formation of
Immunological Synapse
A new layer of complexity in the process of TCR signaling has
come to light in recent years in the form of the immunological
synapse (IS), which has also been referred to as the supramolecular
activation complex (SM C). This is a dynamic yet highly ordered
structure that forms at the site of T cell contact with an antigen-
presenting cell (19). The mature IS is characterized by a central
region (c-SMAC) that is enriched in clustered TCR and PKC#,
surrounded by a peripheral ring (pSMAC) of adhesion factors such
as LFA-1 and a distal ring (dSMAC) containing proteins such as
the tyrosine phosphatases CD148 and CD45. The IS, although not
required for initiating TCR signaling, is required for sustained
signaling, IL-2 production, and proliferation (19). It also has the
ability to act as a positive or negative servo, either amplifying weak
TCR signals or attenuating strong signals (20).
Clustering of lipid rafts at the contact site and formation of the
IS is an active process that requires several upstream signaling
events to occur. Most important of these are the signals that lead to
reorganization of the actin cytoskeleton. The proximal catalyst for
this is the recruitment and activation of the Arp2/3 complex, which
catalyzes the formation of new nucleation sites for actin polymer-
ization. A key upstream regulator of Arp2/3 is WASP, which is
rapidly recruited to lipid rafts following TCR/CD28 costimulation
(13, 21). WASP is constitutively present at high stoichiometry in a
complex with WIP and CrkL. WIP-bound WASP is refractory to
activation. Upon TCR stimulation, this complex is recruited to the
TCR (and consequently to the lipid rafts and the antigen-present-
ing cell contact site) via the binding of the CrkL SH2 domain to
tyrosine-phosphorylated ZAP-70 (22, 23). Co-localization of this
complex with activated PKC# at the lipid rafts results in the
phosphorylation of WIP and disruption of the WIP-WASP associa-
tion, thereby facilitating activation of WASP by Cdc42 (22). In this
model, WIP serves both to keep WASP basally inactive and to
facilitate WASP activation upon TCR stimulation. WASP can also
FIG. 1. T cell receptor signaling
events leading to activation of tran-
scription factors. This figure presents
an overview of some of the key signaling
events linking the binding of peptide-
MHC to the T cell antigen receptor (TCR/
CD3) and the CD4 costimulatory recep-
tor. The existence of key phosphorylation
events is indicated on some of the signal-
ing proteins by small gray circles labeled
P; however, not all proteins undergoing
TCR-stimulated phosphorylation are la-
beled. Ub designates ubiquitination. The
nature of the different interactions is de-
scribed in the accompanying text. For
greater graphical clarity some important
signaling events are not depicted; most
notably the small molecular weight link-
ers Gads and Grb2 are excluded from the
LAT/SLP-76 signalosome complex. Also
not shown are the signals contributed
from the CD28 costimulatory receptor to-
ward the activation of NF"B and the Vav-
1-PI3K positive feedback loop.
Minireview: T Cell Receptor Signaling28828
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HIV is able to co-opt the components of the TCR signaling pathway in 
order to promote effective viral transmission and replication. It has long been 
established that signals emanating from the TCR can upregulate HIV 
transcription (Gruters et al., 1991), however, recent reports implicate TCR 
signaling molecules in the regulation of HIV entry, viral assembly, and 
release. The tyrosine kinase ZAP-70, for instance, has been demonstrated to 
regulate cell-to-cell transmission of HIV through formation of the virological 
synapse, a structure similar to the immunological synapse that forms between 
the infected cell and an uninfected target cell (Sol-Foulon et al., 2007). PIP2 
formation by the lipid kinase PI4P5 kinase Iα has been found to be a 
requirement for HIV entry and infection (Barrero-Villar et al., 2008). The Src 
kinase Lck has been demonstrated to aid in both viral assembly and release 
at the host cell plasma membrane (Strasner et al., 2008). In addition, 
activation of the MAP kinase ERK has been found to be necessary for HIV 
replication and crucial for the prevention of HIV-mediated apoptosis (Furler & 
Uittenbogaart, 2010). Furthermore, it has been demonstrated that signaling 
from the CD28 co-stimulatory receptor can positively and negatively regulate 
HIV transcription (Cook, August, & Henderson, 2002; Cook, Albacker, August, 
& Henderson, 2003; Natarajan, August, & Henderson, 2010). However, 
whether specific stimulatory and co-stimulatory signals at the time of infection 
bias towards productive or latent infection has yet to be investigated. 
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 There is, therefore, a need for further elaboration of the signaling 
pathways that lead to HIV transcriptional regulation and the establishment of 
a productive or latent infection within CD4+ T cells. The current study aims to 
identify the role of TCR activation in determining latency as well as the 
specific pathways through which TCR signaling is regulating transcription.	  
Specific Aims 
One of the most significant obstacles to finding a cure for AIDS is the 
presence of latent reservoirs of HIV infection. Antiretroviral drugs are able to 
prevent ongoing viral replication but are unable to eliminate the virus from 
already infected cells. Therefore, patients’ viral loads are suppressed to 
undetectable levels while on antiretroviral therapy, but, upon cessation of 
therapy, viral loads rebound as the virus is released from latent reservoirs of 
infection. In order to completely eradicate HIV, it is essential to understand 
the mechanisms that contribute to the establishment and maintenance of viral 
latency in the hope of discovering a mechanism for reactivating and 
eliminating the latent reservoir. The purpose of the present study is to 
investigate the mechanisms early in HIV infection that direct the cell towards 
productive or latent infection. 
Specifically, this study aims to: 
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1. Determine whether the strength of signaling at the time of HIV infection 
is correlated with the level of HIV transcription. 
2. Characterize the T cell receptor signaling pathways that regulate HIV 
transcription. 
Understanding the signaling events that lead to the initial establishment of 
latency within newly infected cells is an important step in eliminating the latent 
reservoir and curing AIDS.  
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METHODS 
Establishment of Stable Cell Lines Expressing Chimeric Antigen 
Receptors 
  The laboratory of Dr. Wilson Wong had previously provided chimeric 
antigen receptors (CARs) expressing one of five single-chain variable 
fragments (scFvs) with differing affinities for a shared ligand packaged in phR 
lentiviral vectors driven by a spleen focus-forming virus (SFFV) promoter. The 
CAR-containing lentiviral vectors had then been transduced into a Jurkat E6.1 
T cell line by spinoculation. Three days post-transduction, the cells had then 
been sorted based upon positive expression of the mCherry reporter within 
the CAR using a Legacy MoFlo Cell Sorter by Beckman Coulter. Once sorted, 
cell stocks had been immediately frozen down in order to minimize 
downregulation of the receptors. 
Cell Culture 
 Jurkat E6.1 cells, a CD4+ T cell line, were cultured in RPMI medium 
(Life Technologies) supplemented with 5% Fetal Bovine Serum (FBS), 100 
units/mL of penicillin, 100 µg/mL of streptomycin, and 2mM of L-glutamine in 
250 mL flasks and incubated at 37°C with 5% CO2. Human Embryonic Kidney 
293T (HEK293T) cells were cultured in complete Dulbecco’s Modification of 
Eagle’s Medium (cDMEM, Cellgro) supplemented with 10% FBS, 100 
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units/mL of penicillin, 100 µg/mL of streptomycin, and 2mM of L-glutamine in 
100 mm cell culture dishes and incubated at 37°C with 5% CO2. 
Cell Transfection 
 HEK293T cells were plated in 6-well plates at a density of 3 x 105 cells 
per well in cDMEM and incubated overnight at 37°C with 5% CO2. Cells were 
subsequently transfected with calcium phosphate, 10 µg/mL of NL4-3.Luc 
DNA plasmid, 6 µg/mL of VSV-G DNA plasmid, 2 µg/mL of Rev DNA plasmid, 
and 2 µg/mL of Tat DNA plasmid to produce Vesicular Stomatitis Virus G 
protein (VSV-G) pseudotyped NL4-3.Luc, an Env negative and Nef negative, 
replication incompetent strain of HIV-1. Cells were transfected for five hours, 
the media was replaced with fresh cDMEM, and the cells were incubated 
overnight at 37°C with 5% CO2. Approximately twenty-four hours post-
transfection supernatant was collected and frozen down. 
Inhibitor Assays 
  A 96-well plate was coated with 1 µg/mL of Her2 in a solution of 
phosphate buffered saline (PBS) and incubated overnight at 37°C with 5% 
CO2. On day two, the wells were washed three times with PBS. The plate was 
treated with a 5% FBS-PBS solution and incubated at 37°C with 5% CO2 for 
one hour. 2 x 105 Jurkat cells expressing either the C6.5 or B1D2 chimeric 
antigen receptor were plated in triplicate in VSV-G pseudotyped NL4-3.Luc 
	  26	  
and one of the following conditions: alone, with 1 µM efavirenz, with 10 µM 
PP2, with 10 µM LY294002, or 10 µM staurosporine (Table 1).  
 
Table 1: Plate Map for Inhibitor Assay. Jurkat E6.1 cells expressing either 
the C6.5 or B1D2 CAR were plated in triplicate in the presence of VSV-G 
pseudotyped NL4-3.Luc and an inhibitor. Efz: efavirenz, LY: LY294002, SS: 
staurosporine 	  	  	  	  	  	  	  
 
  
1 2 3 4 5 6 7 8 9 10 11 12
A C6.5 C6.5 C6.5 C6.5 C6.5
B
+ 
HIV
+ 
HIV
+ 
HIV
+ 
HIV
+ 
HIV
C
+ 
Efz
+ 
PP2
+ 
LY
+ 
SS
D B1D2 B1D2 B1D2 B1D2 B1D2
E
+ 
HIV
+ 
HIV
+ 
HIV
+ 
HIV
+ 
HIV
F
+ 
Efz
+ 
PP2
+ 
LY
+ 
SS
G
H
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The plate was incubated overnight at 37°C with 5% CO2. On day three, 
the wells were washed with PBS and treated with a 20% Cell Lysis Buffer-
PBS solution. The plate was spinoculated for one minute, and the contents of 
each well were transferred to a black Costar plate. The plate was treated with 
luciferase and luciferase activity was measured with a Luminometer.  
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RESULTS 
 
 The purpose of our experiment was to determine whether the strength 
of signaling at the time of HIV infection is directly correlated with level of HIV 
transcription and to characterize the T cell receptor signaling pathways that 
regulate HIV transcription. We hypothesized that the strength of signal at the 
time of infection determines the magnitude of early HIV transcription.  
To test our hypothesis, we used a panel of engineered chimeric 
antigen receptors composed of an extracellular Her2 binding domain, 
intracellular CD28 and CD3ζ signaling domains, and an mCherry reporter, 
packaged in a lentiviral vector and expressing differing affinities for the Her2 
ligand (Figure 7). The use of chimeric antigen receptors provided us with a 
model of T cell receptor engagement at the time of HIV infection. The CD28 
and CD3ζ signaling domains enabled us to mimic the activation and co-
stimulation of the T cell receptor while the range of Her2 binding domains 
enabled us to modulate the strength of the signal given to the TCR at the time 
of infection.  
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Figure 7: Structure and Binding Affinities of Chimeric Antigen 
Receptors. A) Representation of Her2 chimeric antigen receptors showing 
extracellular Her2 receptor and intracellular CD28 and CD3ζ with key binding 
domains and tyrosine kinase residues. B) Dissociation constants of Her2 for 
CARs used in experiment. 
 
Jurkat E6.1 T cells that had been previously transduced with either the 
C6.5 or B1D2 chimeric antigen receptor were simultaneously activated with 
Her2 ligand and infected with VSV-G pseudotyped NL4-3.Luc single round 
virus either alone or in the presence of 1 µM efavirenz, 10 µM PP2, 10 µM 
LY294002, or 10 µM staurosporine. Cells infected with virus but not 
stimulated with Her2 served as controls in the first set of experiments, while 
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cells infected with virus and stimulated with Her2 in the absence of an 
inhibitor or in the presence of efavirenz served as controls in the second set 
of experiments. Twenty-four hours post-infection, cells were lysed and 
measured for luciferase activity as an indicator of HIV transcription.  
To test whether the strength of signal at the time of infection directly 
correlates with HIV expression, Jurkat T cells expressing the C6.5 and B1D2 
CARs were infected with NL4-3.Luc in the presence and absence of Her2 
stimulation and HIV expression was measured (Figure 8). In the Her2- control 
condition, there was no difference in the HIV expression of cells expressing 
the low affinity receptor compared with cells expressing the high affinity 
receptor. However, in the presence of Her2 stimulation, there was a 1.5-fold 
increase in the HIV expression of cells expressing the low affinity receptor 
compared to the unstimulated control and a nearly 3-fold increase in the HIV 
expression of cells expressing the high affinity receptor compared to the 
unstimulated control. 
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Figure 8: Effects of Chimeric Antigen Receptor Signaling on HIV 
Transcription. Jurkats expressing C6.5 or B1D2 CARs were infected with 
NL4-3.Luc in the presence and absence of Her2 ligand. 24 hours post-
infection, cells were measured for luciferase activity. Data is representative of 
three separate experiments. 
 
 To begin to characterize the signaling pathways that regulate HIV 
transcription, Jurkat T cells expressing the C6.5 and B1D2 CARs were 
simultaneously infected with NL4-3.Luc and stimulated with Her2 in the 
absence and presence of select inhibitors, and HIV-LUC transcription was 
measured with a luciferase assay. When infected in the presence of the non-
nucleoside reverse transcriptase inhibitor efavirenz, HIV transcription was 
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reduced by 91% in Jurkats expressing the C6.5 CAR and by 96% in Jurkats 
expressing the B1D2 CAR. When infected in the presence of the Src kinase 
inhibitor PP2, HIV transcription was reduced by 61% in Jurkats expressing 
the C6.5 CAR and by 71% in Jurkats expressing the B1D2 CAR. When 
infected in the presence of the PI3K inhibitor LY294002, HIV transcription 
showed no reduction and, in fact, showed a 30% increase in Jurkats 
expressing the C6.5 CAR, while showing a 15% reduction in Jurkats 
expressing the B1D2 CAR. When infected in the presence of the PKC 
inhibitor staurosporine, HIV transcription was reduced by 26% Jurkats 
expressing the C6.5 CAR and by 30% in Jurkats expressing the B1D2 CAR.  
	  33	  
 
 
 
Figure 9: Effects of Chimeric Antigen Receptor Signaling on HIV 
Transcription in the Presence of Inhibitors. Jurkats expressing C6.5 or 
B1D2 CARs were infected with NL4-3.Luc and stimulated with Her2 in the 
absence or presence of an inhibitor. 24 hours post-infection, cells were 
measured for luciferase activity. Data is representative of three separate 
experiments, expect for LY294002 data, which is representative of two 
separate experiments, and staurosporine data, which is preliminary. Efz: 
efavirenz, LY: LY294002, SS: staurosporine 
!
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DISCUSSION 
 
 The AIDS epidemic has claimed the lives of more than 34 million 
individuals worldwide. Although advancements in prevention strategies and 
treatment have led to a steady decline in the rate of AIDS-related deaths in 
recent years, nevertheless, more than a million deaths are attributed to AIDS-
related causes each year. Furthermore, while antiretroviral treatment can 
significantly prolong the lives of individuals with HIV, it is not a cure. Even with 
complete viral suppression to clinically undetectable levels, residual viremia 
remains present in the blood. Upon treatment failure or cessation, viral loads 
rebound to pre-treatment levels within weeks, resulting in a drop in CD4 
counts and the reappearance of symptoms. Therefore, individuals with HIV 
must remain on antiretroviral therapy for the rest of their lives. Yet, the 
problems posed by lifelong treatment, including non-adherence due to the 
high pill burden and tremendous side effect of antiretroviral drugs and, 
conversely, severe adverse effects associated with long-term antiretroviral 
use, make the discovery of a cure essential. 
A significant barrier to curing AIDS is the presence of a latent reservoir 
of cells infected with integrated but transcriptionally silent provirus. Although 
attempts have been made to reactivate the latent reservoir using compounds 
that inhibit key molecules indicated in transcriptional repression leading to the 
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maintenance of latency, none have shown a significant reduction in the latent 
reservoir. The unsuccessfulness of efforts to reactivate the latent reservoir 
highlights the need for a better understanding of transcriptional repression 
and its role in latency. In particular, insight into the molecular events that lead 
to the initial establishment of latency at the time of infection could lead to the 
discovery of novel therapeutic targets aimed at elimination of the latent 
reservoir and eradication of the virus. Preliminary research from our lab has 
indicated CD4+ T cell activation at the time of infection as a possible 
determinant to the establishment of productive or latent infection, which led to 
the current study investigating the influence of T cell receptor signaling on 
HIV transcription. 
Initial infection of Jurkat E6.1 T cells expressing the C6.5 or B1D2 
chimeric antigen receptor revealed that stimulation of the C6.5 low affinity 
receptor at the time of infection led to a 1.5-fold increase in HIV transcription 
compared to the unstimulated control, whereas stimulation of the high affinity 
receptor at the time of infection led to a nearly 3-fold increase in HIV 
transcription compared to the unstimulated control. These findings support 
our hypothesis that the strength of signaling at the time of infection 
determines the magnitude of HIV transcription as increased signaling leads to 
the activation of pathways that positively regulate HIV transcription shortly 
after infection. Future experiments to determine whether the differences in 
HIV transcription correspond with latency will be conducted by equally 
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reactivating Jurkats expressing C6.5 and B1D2 CARs with CD3/28 antibody 
beads. We hypothesize that signaling through the low affinity receptor biases 
cells toward latent infection while signaling through the high affinity receptor 
biases cells toward productive infection. Therefore, we expect reactivated 
Jurkats expressing the C6.5 CAR to show a greater percentage increase in 
HIV transcription than reactivated Jurkats expressing the B1D2 CAR. 
Furthermore, additional experiments will be conducted with Jurkats 
expressing mid-range affinity CARs in order to determine whether the 
strength of signaling directly correlates with HIV expression. However, 
preliminary data from Jurkats expressing the ML3-9 and H3-B1 mid-range 
affinity receptors revealed HIV transcription levels comparable to those from 
Jurkats expressing the C6.5 low affinity receptor. These preliminary results 
suggest the possibility of a signaling threshold, whereby sub-optimal 
stimulation below the threshold biases the cell towards transcriptional 
repression while stimulation above the threshold biases the cell towards 
transcriptional activation. Further experiments need to be conducted to test 
the hypothesis of a signaling threshold. 
Simultaneous infection and stimulation of Jurkat E6.1 T cells 
expressing the C6.5 or B1D2 chimeric antigen receptor in the presence of the 
Src kinase inhibitor PP2 revealed a 61% reduction in HIV transcription in 
Jurkats expressing the C6.5 receptor compared with the uninhibited control 
and a 71% reduction in HIV transcription in Jurkats expressing the B1D2 
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receptor compared with the uninhibited control. These findings indicate that 
the Src kinase inhibitor PP2 diminishes the transcriptional effects of the CARs 
and support the hypothesis that HIV transcription is regulated through TCR 
signaling, as the Src kinase Lck is an early activator in the TCR signaling 
pathways. Therefore, if TCR signaling is indeed mediating the regulation of 
HIV transcription, Lck inhibition would lead to the inhibition of Lck-activated 
downstream pathways within the TCR signaling cascade. The reduction in 
HIV transcription upon addition of the Src kinase inhibitor PP2 seen in our 
experiments is consistent with this hypothesis. 
Simultaneous infection and stimulation of Jurkat E6.1 T cells 
expressing the C6.5 or B1D2 chimeric antigen receptor in the presence of the 
PI3 kinase inhibitor LY294002 revealed a 30% increase in HIV transcription in 
Jurkats expressing the C6.5 receptor compared with the uninhibited control 
and a 15% reduction in HIV transcription in Jurkats expressing the B1D2 
receptor compared with the uninhibited control. These findings indicate that 
PI3 kinase inhibition enhances HIV transcription in the Jurkats expressing the 
low affinity receptors while slightly repressing HIV transcription in the Jurkats 
expressing the high affinity receptors. The upregulatory effects of PI3 kinase 
inhibition are consistent with previous findings from our lab that PI3 kinase 
recruitment to CD28 represses HIV transcription while inhibition of PI3 kinase 
leads to enhanced HIV transcription (Cook et al., 2002). This would suggest 
that the TCR and CD28 co-stimulatory receptor are signaling through the PI3 
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kinase pathway to negatively regulate HIV transcription. The mechanism for 
the repressive effects on HIV transcription seen in the Jurkats expressing the 
high affinity receptors is less obvious. It is possible that signaling through the 
high affinity receptor is producing a saturating effect on the upregulation of 
HIV transcription, and, therefore, inhibition of a transcriptional repressor is 
unable to further increase HIV transcription. The mechanisms by which PI3 
kinase lead to a decrease in HIV transcription in this situation is unclear and 
needs to be investigated further.  
Simultaneous infection and stimulation of Jurkat E6.1 T cells 
expressing the C6.5 or B1D2 chimeric antigen receptor in the presence of the 
protein kinase C inhibitor staurosporine revealed a 26% reduction in HIV 
transcription in Jurkats expressing the C6.5 receptor compared with the 
uninhibited control and a 30% reduction in HIV transcription in Jurkats 
expressing the B1D2 receptor compared with the uninhibited control. These 
findings indicate that PKC inhibition modestly represses HIV transcription and 
suggest that the TCR is signaling, at least in part, through the PKC pathway 
of the TCR signaling cascade. The lesser effect of PKC inhibition on HIV 
transcription as compared to the effect of Src kinase inhibition could be due to 
the fact that, while the Src kinase Lck is upstream within the signaling 
cascade and common to multiple signaling pathways, PKC is downstream 
within one of several signaling pathways. Therefore, inhibiting Lck would 
inhibit multiple Lck-activated pathways within the signaling cascade while 
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inhibiting PKC would only inhibit the PKC activated pathways. This suggests 
the possibility that signaling has a combinatorial effect on HIV transcription 
regulation, involving multiple pathways within the TCR signaling cascade. 
Further experiments to determine the roles of different TCR signaling 
pathways on HIV transcription will be conducted using inhibitors to 
downstream targets within the PKC pathway, MAP kinase inhibitors, and 
inhibitors to targets within the IP3/calcium mobilization pathway. In addition, 
experiments using combinations of inhibitors from multiple pathways should 
be conducted in order to test the combinatorial effects of signaling on HIV 
transcription. 
 Overall, the current study provides evidence for the regulation of HIV 
transcription through T cell receptor signaling pathways and suggests that 
TCR signaling at the time of HIV infection may be a determinant of latency. 
Further characterization of the specific TCR signaling pathways that lead to 
activation or repression of HIV transcription could lead to novel strategies 
aimed at eliminating the latent reservoir. 
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